Immutep Stock Price, News & Analysis (NASDAQ:IMMP)

$1.81 +0.02 (+1.12 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.81
Today's Range$1.77 - $1.82
52-Week Range$1.25 - $3.24
Volume17,429 shs
Average Volume21,344 shs
Market Capitalization$42.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28

About Immutep (NASDAQ:IMMP)

Immutep logoImmutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:IMMP
CUSIPN/A
Phone+61-2-83157003

Debt

Debt-to-Equity Ratio0.22%
Current Ratio6.06%
Quick Ratio6.06%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.18 million
Price / Sales13.34
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book2.13

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees17
Outstanding Shares23,430,000

Immutep (NASDAQ:IMMP) Frequently Asked Questions

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Where is Immutep's stock going? Where will Immutep's stock price be in 2018?

3 equities research analysts have issued 1-year target prices for Immutep's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Immutep's stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Immutep.

Who are some of Immutep's key competitors?

Who are Immutep's key executives?

Immutep's management team includes the folowing people:

  • Marc Voigt, Chief Executive Officer, Executive Director (Age 42)
  • Deanne Miller, Chief Operating Officer, General Counsel, Company Secretary (Age 39)
  • Frederic Triebel M.D., Ph.D., Chief Scientific Officer & Chief Medical Officer (Age 61)
  • Russell John Howard Ph.D., Non-Executive Chairman of the Board (Age 65)
  • Pete A. Meyers, Non-Executive Deputy Chairman of the Board (Age 47)
  • Grant Chamberlain, Non-Executive Director

How do I buy Immutep stock?

Shares of Immutep can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immutep's stock price today?

One share of Immutep stock can currently be purchased for approximately $1.81.

How big of a company is Immutep?

Immutep has a market capitalization of $42.95 million and generates $3.18 million in revenue each year. Immutep employs 17 workers across the globe.

How can I contact Immutep?

Immutep's mailing address is Plaza Building, L 12 95 Pitt St, SYDNEY, NSW 2000, Australia. The biotechnology company can be reached via phone at +61-2-83157003 or via email at [email protected]


MarketBeat Community Rating for Immutep (IMMP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Immutep and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immutep (NASDAQ:IMMP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.33$7.00$7.00$7.00
Price Target Upside: 253.82% upside228.64% upside228.64% upside288.89% upside

Immutep (NASDAQ:IMMP) Consensus Price Target History

Price Target History for Immutep (NASDAQ:IMMP)

Immutep (NASDAQ:IMMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018Maxim GroupReiterated RatingBuy -> Buy$7.00 -> $5.00MediumView Rating Details
4/19/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/28/2017HC WainwrightSet Price TargetBuy$8.00N/AView Rating Details
8/26/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Earnings History for Immutep (NASDAQ:IMMP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Immutep (NASDAQ:IMMP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Immutep (NASDAQ:IMMP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immutep (NASDAQ IMMP)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Immutep (NASDAQ IMMP) News Headlines

Source:
DateHeadline
Zacks: Brokerages Set $5.00 Target Price for Immutep Ltd (IMMP)Zacks: Brokerages Set $5.00 Target Price for Immutep Ltd (IMMP)
www.americanbankingnews.com - February 19 at 7:34 AM
Immuteps (IMMP) "Buy" Rating Reaffirmed at Maxim GroupImmutep's (IMMP) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - February 15 at 6:52 PM
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical TrialOutcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
finance.yahoo.com - February 9 at 9:10 AM
Immutep Limited Announces Milestone Payment From Chinese Partner EOC PharmaImmutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma
finance.yahoo.com - February 8 at 4:26 PM
Maxim Group Reiterates Buy Rating for Immutep (IMMP)Maxim Group Reiterates Buy Rating for Immutep (IMMP)
www.americanbankingnews.com - February 1 at 4:58 PM
 Immutep Ltd (IMMP) Given Consensus Recommendation of "Strong Buy" by Brokerages Immutep Ltd (IMMP) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 31 at 11:12 PM
Critical Analysis: Immutep (IMMP) & ArQule (ARQL)Critical Analysis: Immutep (IMMP) & ArQule (ARQL)
www.americanbankingnews.com - January 30 at 9:32 AM
Zacks: Analysts Set $7.00 Target Price for Immutep Ltd (IMMP)Zacks: Analysts Set $7.00 Target Price for Immutep Ltd (IMMP)
www.americanbankingnews.com - January 26 at 3:12 AM
Zacks: Immutep Ltd (IMMP) Given $7.00 Average Price Target by AnalystsZacks: Immutep Ltd (IMMP) Given $7.00 Average Price Target by Analysts
www.americanbankingnews.com - January 19 at 7:08 PM
Zacks: Immutep Ltd (IMMP) Receives Average Rating of "Strong Buy" from AnalystsZacks: Immutep Ltd (IMMP) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 15 at 5:08 PM
Zacks: Brokerages Set $7.00 Price Target for Immutep Ltd (IMMP)Zacks: Brokerages Set $7.00 Price Target for Immutep Ltd (IMMP)
www.americanbankingnews.com - January 11 at 8:19 AM
Pluristem Therapeutics (PSTI) vs. Immutep (IMMP) Head to Head ReviewPluristem Therapeutics (PSTI) vs. Immutep (IMMP) Head to Head Review
www.americanbankingnews.com - January 9 at 9:30 PM
Operational Update Nasdaq:IMMP - GlobeNewswire - GlobeNewswire (press release)Operational Update Nasdaq:IMMP - GlobeNewswire - GlobeNewswire (press release)
globenewswire.com - December 12 at 8:04 AM
 Brokerages Set $7.00 Target Price for Immutep Ltd (IMMP) Brokerages Set $7.00 Target Price for Immutep Ltd (IMMP)
www.americanbankingnews.com - December 6 at 2:50 PM

SEC Filings

Immutep (NASDAQ:IMMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immutep (NASDAQ:IMMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immutep (NASDAQ IMMP) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.